IBAB Ion Beam Applications SA

IBA signs contract to install a Be-Efficient irradiation solution in Germany

IBA signs contract to install a Be-Efficient irradiation solution in Germany

Louvain-la-Neuve, Belgium, March 19, 2024 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today it has signed a contract for the installation of a Be-Efficient electron beam irradiation solution equipped with two Rhodotron® accelerators in Germany.

This Be-Efficient electron beam solution includes two Rhodotron® accelerators, a Beagle® production line control system and a Building Safety System. The Be-Efficient solution will be used for e-beam irradiation for polymer crosslinking applications, which enhances the resistance of polymers.

The typical price for a Be-Efficient irradiation solution ranges from EUR 11 million to EUR 18 million, depending on the configuration and options. In addition to this contract, IBA also recently received the first payment for another contract, signed at the end of December 2023, for the installation of Be-Wide X-ray irradiation solution in the USA.

Thomas Servais, President of IBA Industrial Solutions, commented: “We are very pleased to be supporting another company with our cutting-edge technology. Our Be-Efficient irradiation solution will be integrated into a center promoting more sustainable technology. Using electron beams in the irradiation process is an environmentally friendly alternative to traditional chemical crosslinking, as well as being safe for the end consumer.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

CONTACTS

Soumya Chandramouli

Chief Financial Officer



Olivier Lechien

Corporate Communication Director



ICR Consilium

Amber Fennell, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
19/03/2024

Underlying

IBABIon Beam Applications SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 2nd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effect...

March 2, 2026 1 EN
 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 2 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à parti...

March 2, 2026 1 EN
 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 25, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 13, 2026. In its notification, Premier Miton Group plc indi...

February 25, 2026 1 EN
 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 25 février 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçue le ...

February 25, 2026 1 EN
 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 23rd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 20...

February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch